Robert R. Bonczek
Taiwan liposaomal Companies
is president, CFO, and general counsel at b3bio, Inc., a biotechnology company, and founding partner and president of AspenTree Capital, a boutique investment company. His past experience includes being CFO and general counsel at Trimeris, Inc., where he helped the biotechnology company through an IPO, secondary equity offerings, additional private placements, and a major collaboration agreement with Roche, as well as other collaborations. He has also served as a full-time legal consultant to Wilmer Hale and worked with Donaldson, Lufkin & Jenrette in their merchant banking area. Prior to that, Mr. Bonczek held various executive-level roles, including chief counsel and worldwide director of safety, health and environmental affairs at DuPont/Conoco. Mr. Bonczek serves on a number of boards including b3 bio, AspenTree Capital, ELS Services, and K2 Pure; he is also on the advisory boards of Caxton Advantage Healthcare Fund and Centre Partners. He earned degrees in chemistry and law from the University of North Carolina at Chapel Hill and an MBA from the Wharton School at the University of Pennsylvania.
operation and management of modern Chinese medicine enterprises